Navigation Links
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Date:3/10/2008

New 2.25 mm Diameter Stent Now Available in Europe, Asia and Latin America

ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting Coronary Stent System, offering physicians a smaller stent based upon the proven efficacy, positive safety results and excellent deliverability of XIENCE V. The addition of the 2.25 mm stent to the XIENCE V portfolio gives physicians access to a wider range of stent sizes for treating a variety of patient types.

"Lesions in small vessels tend to be more complex and challenging to treat, so it's important to have a drug eluting stent with proven clinical benefits that can be easily delivered to the diseased area of the vessel," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "With XIENCE V 2.25 mm, physicians now have access to a smaller stent that combines these critical attributes with the positive safety outcomes we have seen with XIENCE V. These outcomes include low rates of reintervention in the diseased vessel, low rates of heart attack and death, and low rates of vessel renarrowing following treatment."

The 2.25 mm version of the XIENCE V stent will be launched immediately in the majority of European markets and select countries in Asia and Latin America. In addition to the 2.25 mm stent, XIENCE V is available in stent diameters of 2.5 mm, 2.75 mm, 3.0 mm, 3.5 mm and 4.0 mm for lesions 28 mm or shorter.

Coronary artery disease (CAD) occurs when arteries become narrow due to plaque buildup, restricting blood flow to the heart. Approximately 30 to 40 percent of CAD lesions occur in vessels equal to or less than 2.5 mm in diameter.

XIENCE V is the only drug eluting stent to demonstrate superiority over another drug eluting stent in a randomized clinical trial. In the SPIRIT family of trials, XIENCE V demonstrated:
-- Superiority for XIENCE V compared to TAXUS(R) paclitaxel eluting

coronary stent system in the primary endpoint of angiographic In-Stent

Late Loss in the SPIRIT II clinical trial at six months, with a

statistically significant 69 percent reduction for XIENCE V. In-stent

late loss is a measure of vessel renarrowing within the margins of the

stent.

-- Superiority for XIENCE V compared to the TAXUS in the primary endpoint

of angiographic In-Segment Late Loss at eight months in the SPIRIT III

clinical trial, with a statistically significant 50 percent reduction

for XIENCE V. In-segment late loss is a measure of vessel renarrowing.

-- An observed 43 percent reduction in major adverse cardiac events (MACE)

compared to TAXUS at one year in SPIRIT III. MACE is an important

clinical measure of safety and efficacy outcomes for patients, and is

defined as cardiac death, heart attack (myocardial infarction or MI),

or ischemia-driven target lesion revascularization (TLR associated with

symptoms or documented lack of blood supply).

-- Non-inferiority to TAXUS with an observed 23 percent reduction in

Target Vessel Failure (TVF) for XIENCE V compared to TAXUS in the

SPIRIT III clinical trial at one year. Target Vessel Failure is a

measure of re-treatment anywhere within the target vessel and includes

cardiac death or heart attack.

Additionally, data from an independent pooled subset analysis of SPIRIT II and SPIRIT III at one year showed:
-- A statistically significant 59 percent reduction in angiographic

In-Stent Late Loss for XIENCE V compared to TAXUS for lesions in a

reference vessel diameter less than 2.5 mm.

-- An observed 61 percent reduction in angiographic In-Segment Late Loss

for XIENCE V compared to TAXUS for lesions in a reference vessel

diameter less than 2.5 mm.

XIENCE V was launched in Europe and other international markets in late 2006.

XIENCE V is an investigational device in the United States and Japan, and is currently under review for approval by the U.S. Food and Drug Administration.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Announces 10.8 Percent Increase in Quarterly Dividend
4. On Valentines Day, Abbott Urges Women to Take Heart With Launch of Faces of Heart Disease Exhibit to Raise Heart Health Awareness
5. Abbott Goes Red to Educate Bay Area Women About Heart Disease
6. Abbott to Present at Merrill Lynch Healthcare Conference
7. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
8. Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings
9. Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS
10. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
11. The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 , ... ... decreases in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Workers Compensation Research Institute (WCRI) . , According to the study, medical payments per ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning ... the Cape Coral area, is embarking on a charity drive with the goal of ... The Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized by ... Workplaces National Standard. To learn more about Diplomat,s ... ... ... administered by WorkplaceDynamics, LLC, a research firm specializing in organizational health ...
(Date:12/8/2016)... Connecticut , 8 de dezembro de 2016  A Mederi Therapeutics ... terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  A new ... reports that the use of opioid therapy to treat ... increase the likelihood of more harmful consequences, including death. ... , M.D., and Zankhana Mehta , M.D., authored ... research on chronic opioid therapy. The study was published ...
Breaking Medicine Technology: